If Heckmann changing its name wasn't confusing enough for investors, it appears as though Nuverra Environmental Solutions (NYSE: NES ) will be venturing into a new business. The company just�purchased�a greenfield disposal facility that it will use for solid and oil waste from drilling operations. While the potential revenue for the company doesn't really move the needle for the company, the move is more important for the new image that Nuverra wants to reflect to its customers.�
Nuverra wants to be the one-stop shop for any waste-related business in the oil and gas industry, and this move is a step in that direction. In this video, Fool.com contributor Tyler Crowe looks at how this will fit into the company's business model and what investors in the company should watch for in the future.
No matter what niche product an oil services company may offer its clients, it's almost guaranteed that Halliburton is a main competitor. Halliburton, one of the top companies in the business, is one of the most complete oil services companies around, providing customers with a wide array of services. To access The Motley Fool's new premium research report on this industry stalwart, simply click here now and learn everything you need to know about how Halliburton is positioning itself both at home and abroad.
Top 5 Media Stocks To Watch For 2015: Foundation Medicine Inc (FMI)
Foundation Medicine, Inc., incorporated on November 12, 2009, is a commercial-stage company. The Company is focused on fundamentally changing the way patients with cancer are treated. The Company�� platform includes methods and algorithms for analyzing tumor tissue samples across all types of cancer, as well as information aggregation and concise reporting capabilities. Its products provide genomic information about each patient�� individual cancer, enabling physicians to optimize treatments in clinical practice and enabling biopharmaceutical companies to develop targeted oncology therapies more effectively.
FoundationOne, its first clinical product, is, to its knowledge, the only commercially available comprehensive molecular information product designed for use in the routine care of patients with cancer. In addition, the Company is considered a non-contracting provider by commercial third-party payors because it has not entered into specific contracts to provide FoundationOne to their covered patients, and as a result it takes on primary responsibility for obtaining reimbursement on behalf of patients.
Advisors' Opinion:- [By RedChip]
According to Walter Isaacson�� biography, Steve Jobs paid a reported $100,000 to learn the DNA sequence of his cancer. This work, completed at MIT and Harvard, led to the launch of Foundation Medicine (NASDAQ: FMI). Foundation Medicine has grabbed headlines over the past couple of weeks as it entered the capital markets with a high-profile IPO led by Goldman Sachs.
- [By John Udovich]
If you have not been watching the biotech sector lately, you should start paying attention as the sector along with small cap biotech stocks like Cell Therapeutics Inc (NASDAQ: CTIC), BIND Therapeutics Inc (NASDAQ: BIND) and TNI BioTech (OTCMKTS: TNIB) continue to produce a steady stream of good news for investors thanks to positive industry trends. Moreover, Ophthotech Corp (NASDAQ: OPHT), Foundation Medicine Inc (NASDAQ: FMI), Evoke Pharma and Fate Therapeutics Inc (NASDAQ: FATE) are this week's biotech IPOs that will no doubt be watched closely by Wall Street and industry observers in general. With that in mind, consider the following biotech news or recent articles about the industry and the small cap players in it:
- [By John Udovich]
Small cap healthcare information stocks Everyday Health Inc (NYSE: EVDY), Foundation Medicine Inc (NASDAQ: FMI) and CollabRx Inc (NASDAQ: CLRX) help consumers and healthcare professionals deal with the increasing amount of information overload that comes with treating or figuring out how to treat patients.
5 Best Oil Service Stocks To Own Right Now: ChannelAdvisor Corp (ECOM)
Channeladvisor Corporation, incorporated on June 18, 2001, is a provider of software-as-a-service, or SaaS, solutions that enables retailers and manufacturer customers to integrate, manage and optimize their merchandise sales across hundreds of online channels. Through the Company�� platform, the Company enables its customers to connect with new and existing sources of demand for their products, including e-commerce marketplaces, such as eBay, Amazon and Newegg, search engines and comparison shopping websites, such as Google, Microsoft�� Bing, and Nextag, and emerging channels, such as Facebook and Groupon.
The Company serves customers across a range of industries and geographies. As of December 31, 2012, the Company had over 1,900 customers worldwide. Its customers include both traditional and online retailers, such as Ann Taylor, eBags.com, J&R Electronics and Jos. A. Bank Clothiers, as well as manufacturers of consumer goods, such as Dell, Dooney and Bourke, Lenovo, Sony and Under Armour.
The Company�� suite of SaaS solutions allows its customers to more easily integrate, manage and optimize their online sales across hundreds of available channels through a single, integrated platform. Its suite solutions includes a number of individual offerings, or modules. Each module integrates with a particular type of channel, such as third-party marketplaces, paid search or comparison shopping websites, or supports specific online functionality, such as creating webstores or employing rich media solutions on their websites. The Company provides its customers with a single Web-based interface as the central location for them to control, analyze and manage their online sales across hundreds of available channels and multiple geographies. It provides its customers with actionable insights across the latest channel and consumer trends and general product performance, which enables them to evaluate and, if necessary, improve the efficiency of their business rules on existing or new! channels.
Advisors' Opinion:- [By Jonas Elmerraji]
Cloud software provider ChannelAdvisor (ECOM) has enjoyed a stellar run since its IPO earlier this year. In the months since ECOM started trading at the beginning of the summer, shares have nearly doubled. But this stock could be headed for even higher ground before the calendar flips over to 2014.
That's because ECOM is currently forming an ascending triangle pattern, a bullish price setup that's formed by a horizontal resistance level above shares at $40 and uptrending support to the downside. Basically, as ECOM bounces in between those two technically significant price levels, it's getting squeezed closer and closer to a breakout above resistance. When that happens, we've got a buy signal in shares.
ChannelAdvisor has shown investors excellent relative strength all the way up this year, but it's worth noting that the uptrend in ECOM's relative strength line has remained intact even while the ascending triangle has been forming – that's a big sign of strength in this market. I'd recommend buying on a move through $40, from there, keep a protective stop at the 200-day moving average.
- [By David Zeiler]
5. ChannelAdvisor Corp. (NYSE: ECOM): ChannelAdvisor provides web-based merchandise management software to businesses like retailers and manufacturers. ECOM (get it, e-commerce) went public May 23 at $14 a share and rose 31.7% on its first day. It currently trades at about $37.57, putting it up 168.36% over its offer price.
5 Best Oil Service Stocks To Own Right Now: Enanta Pharmaceuticals Inc (ENTA)
Enanta Pharmaceuticals, Inc., incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. The Company is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes-protease (partnered with AbbVie, the former research-based pharmaceutical business of Abbott Laboratories), NS5A (partnered with Novartis) and nucleotide polymerase, as well as a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin. ABT-450, discovered through its collaboration with AbbVie, is a protease inhibitor that has demonstrated in vitro potency against known resistant HCV mutants.
In Phase I studies, ABT-450 co-administered with ritonavir, a commonly used boosting agent to increase the blood concentrations of many protease inhibitors, was shown to be safe and well tolerated. Co-administration of ABT-450 with ritonavir, which it refers to together as ABT-450/r, has enabled once-daily dosing of ABT-450. Phase II studies have demonstrated the efficacy of ABT-450/r in patients with chronic HCV, and other interferon-free Phase II studies of ABT-450-containing regimens continue. AbbVie is developing a next-generation protease inhibitor discovered within the Enanta-AbbVie collaboration. EDP-239 is the NS5A inhibitor discovered by the Company. The Company also has a program to develop nucleotide inhibitors to HCV NS5B polymerase, which is another DAA mechanism considered to have a barrier to resistance. The Company�� Bicyclolide antibiotic product candidate is EDP-788, which it is developing for use as an intravenous drug in the hospital setting and for oral dosing in the home setting. EDP-788 is a prodrug, which means that it is inactive until it is converted in the body into an active compound. EDP-788 is! a water-soluble molecule which, when administered in preclinical models, is cleanly and rapidly converted into the active compound.
Advisors' Opinion:- [By George Budwell]
Normally, such strong efficacy results would be hailed as a major achievement. However, these results are actually less impressive than those by competing drug's developed by AbbVie (NYSE: ABBV ) , Enanta Pharmaceuticals (NASDAQ: ENTA ) and Gilead. Bristol-Myers' therapy also has a treatment duration double that of Gilead's drug Sovaldi for genotype 1 patients. So, while these results are impressive in their own right, the therapy's commercial prospects may be limited due to the presence of superior competitors in the market.�
- [By Sean Williams]
The next big thing in treating hepatitis-C
The other currently experimental therapy very likely to make it onto the FDA's desk before the midpoint of 2014 is AbbVie's (NYSE: ABBV ) direct-acting antiviral combo drug. In similar fashion to Sovaldi, this DAA-combo therapy, which includes ABT-450 from Enanta Pharmaceuticals (NASDAQ: ENTA ) , is running six confirmatory late-stage trials on various genotypes. There are, however, two primary differences between AbbVie's DAA-combo therapy and Sovaldi. - [By James Fink]
And lastly I'll go into healthcare, which is kind of a growth cyclical type name. It's partially defensive, partially growth. I think the more growth-oriented section of healthcare would be biotech, and right now, a very promising biotech stock is Enanta Pharmaceuticals. That's a NASDAQ stock; ticker symbol (ENTA).
5 Best Oil Service Stocks To Own Right Now: Monro Muffler Brake Inc.(MNRO)
Monro Muffler Brake, Inc. provides automotive undercar repair and tire services. The company offers a range of services on passenger cars, light trucks, and vans for brakes; mufflers and exhaust systems; and steering, drive train, suspension, and wheel alignment. It also provides other products and services, including tires and routine maintenance services, including state inspections. The company?s maintenance services include oil change, heating and cooling system flush and fill service, belt installation, fuel system service, and a transmission flush and fill service. In addition, it replaces and services batteries, starters, and alternators, as well as offers air conditioning services. As of June 25, 2011, the company had 802 company-operated stores and 3 franchised locations. It operates stores primarily under the Monro Muffler Brake & Service, Tread Quarters Discount Tire, Mr. Tire, Autotire Car Care Center, and Tire Warehouse names in New York, Pennsylvania, Ohio, Connecticut, Massachusetts, West Virginia, Virginia, Maryland, Vermont, New Hampshire, New Jersey, North Carolina, South Carolina, Indiana, Rhode Island, Delaware, Maine, Illinois, and Missouri. Monro Muffler Brake, Inc. was founded in 1957 and is headquartered in Rochester, New York.
Advisors' Opinion:- [By Jeremy Bowman]
What: Shares of Monro Muffler Brake (NASDAQ: MNRO ) were going in reverse today, falling as much as 11% after missing on all counts in its earnings report.
- [By kcpl]
Monro Muffler Brake (MNRO) is a popular name in the DIFM & Services segment, while Pep Boys - Manny, Moe & Jack (PBY) is a hybrid of DIFM-DIY. The present perspective seems bright for such aftermarket service providers. However, these two are entirely different from aftermarket retailers such as Advance Auto Parts (AAP). Let us take a look at the present aftermarket scenario and its prospects.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Monro Muffler Brake (Nasdaq: MNRO ) , whose recent revenue and earnings are plotted below.
No comments:
Post a Comment